Chemical compounds targeting the eye and use thereof in the treatment of eye diseases

1. Chemical compound having the following general formula (I):

where COR is a secondary or tertiary amide, such that —R is chosen from:

M; —NH—(CH 2 ) n -M and —NH—(CH 2 ) n —C(CH 3 )(CH 3 )-M, -M being chosen from

a)

wherein,

R 1 is chosen from an oxygen atom, a sulfur atom, a >CH 2 , >CH—O—(CH 2 ) n —CH 3 , >CH—(CH 2 ) n —O—(CH 2 ) n —CH 3 , >CH—(CH 2 ) n —OH, >CH—COOH, >C(OH)phenyl or >NH group;

R 3 is chosen from a hydrogen atom, a C 1 -C 6 alkyl, —OH or C 1 -C 6 —O-alkyl group;

R 4 is chosen from a hydrogen atom, a C 1 -C 6 alkyl, —OH or C 1 -C 6 —O-alkyl group;

n is an integer comprised between 0 and 6;

—NH—(CH 2 ) n —W, W being a hydrogen atom, or a —OH group, a —O—(CH 2 ) n —CH 3 group, or a group chosen from

i)

wherein,

R 1 is chosen from an oxygen atom, a sulfur atom, a >CH 2 , >CH—O—(CH 2 ) n —CH 3 , >CH—(CH 2 ) n —OH, >CH—COOH, >C(OH)phenyl or >NH group;

R 3 is chosen from a hydrogen atom, a C 1 -C 6 alkyl, —OH or C 1 -C 6 —O-alkyl group;

R 4 is chosen from a hydrogen atom, a C 1 -C 6 alkyl, —OH or C 1 -C 6 —O-alkyl group;

R 5 is chosen from a —CH 3 , —OH, —O—(CH 2 ) n —CH 3 , —(CH 2 ) n —OH or —COOH group;

n is an integer comprised between 0 and 6;

as well as the pharmaceutically acceptable salts of said chemical compound.

2. Chemical compound having the general formula (I) according to claim 1 , chosen from the following chemical compounds:

1-[2-methoxyethanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[1,4-oxazinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[piperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[2-hydoxyethanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1 [1,4-oxazepanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-thiomorpholinamido-(2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-pyrrolidinamido-(2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[2-morpholinopropanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[(S)-3-hydroxypyrrolidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[2-morpholinoethanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[(R)-3-hydroxypyrrolidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-hydroxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[2-methyl-2-(4-morpholinyl) propylamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-hydroxymethylpiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[(Z)-2,6-dimethylmorpholinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-hydroxyphenylamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-benzyl-4-hydroxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-carboxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[(E)-4-hydroxycyclohexamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[3-methoxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8, 10, 12,14, 16, 18-nonaenedioate;

1-[4-methoxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[2-(2-furyl)ethanamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-n-propoxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate;

1-[4-ethylmethoxypiperidinamido](2E,4E,6E,8E,10E,12E,14E,16Z,18E)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioate.

3. Composition comprising at least one said chemical compound according to claim 1 .

4. The composition according to claim 3 comprising at least one excipient.

5. The composition according to claim 3 , comprising a support in a form adapted to be ingested, injected into the eye or injected into the blood.

6. A drug comprising the chemical compound having the general formula (I) according to claim 1 .

7. A method for the photoprotection of the cells of the retinal pigment epithelium in mammals, comprising administering to said cells an effective amount of the chemical compound having the general formula (I) of claim 1 .

8. A method for the treatment and/or the prevention of damage to the retina of mammals caused by exposure to blue light corresponding to the blue band of the visible light spectrum, of a wavelength comprised between 435 nm and 490 nm, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

9. A method for the treatment and/or the prevention of damage to the retina of mammals caused by retinal degenerations, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

10. A method for treatment and/or the prevention of eye diseases in mammals, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

11. A method for treatment and/or the prevention of retinopathies in mammals, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

12. A method for treatment and/or the prevention of age-related macular degeneration (AMD) in mammals, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

13. A method for treatment and/or the prevention of Stargardt's disease and Retinitis pigmentosa in mammals, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 1 to a patient in need thereof.

14. Composition comprising at least one said chemical compound according to claim 2 .

15. The composition according to claim 4 , comprising a support in a form adapted to be ingested, injected into the eye or injected into the blood.

16. A drug comprising the chemical compound having the general formula (I) according to claim 2 .

17. A drug comprising composition of claim 3 .

18. A method for the photoprotection of the cells of the retinal pigment epithelium in mammals, comprising administering to said cells an effective amount of the chemical compound having the general formula (I) of claim 2 .

19. A method for the photoprotection of the cells of the retinal pigment epithelium in mammals, comprising administering to said cells an effective amount of the composition of claim 3 .

20. A method for the treatment and/or the prevention of damage to the retina of mammals caused by exposure to blue light corresponding to the blue band of the visible light spectrum, of a wavelength comprised between 435 nm and 490 nm, comprising administering an effective amount of the chemical compound having the general formula (I) of claim 2 to a patient in need thereof.